Rituximab, a monoclonal anti-CD20 antibody, is highly effective in treatment of MuSK-MG and PV and appears to show its beneficial effects, at least partially, through repopulation of diminished IL-10 producing B cells (81). Here, IL10 is linked to acquired polycythemia vera.